Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1100 participants.

Also called NCT02722447

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,100 participants (planned count) (from the registry)
Sponsor
Walter Ageno (from the registry)
Registry
  • NCT NCT02722447
Other papers using this trial's data
  • Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial BMJ (Clinical research ed.), 2022-11-23 DOI, PubMed 36520715, PMC9682494 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02722447. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2019-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
Acronym
RIDTS
Intervention (Drug)
rivaroxaban
Intervention (Drug)
Placebo
Lead sponsor
Walter Ageno (class: other)

Record details

Record id
cardio:ct-nct02722447
Content hash
6cc0f42c95be21a27377b9ee51a5e2ee1bfec1870e804d3ebe483217d31bd9a2